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WHAT’s NEW? 
RasGAP family members are negative modulators of Ras, an oncogene expressed by many tumors. The 
p120 RasGAP protein was the first identified RasGAP family member. Beyond regulation of Ras, p120 
RasGAP triggers various signaling cascades and, as a caspase-3 substrate, plays important roles in stress 
sensing. Here we report that fragment N2, a p120 RasGAP fragment generated by caspase-3, prevents 
metastatic progression. This indicates that stress, via activation of caspase-3, can generate metastasis 
suppressor responses. 
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ABSTRACT 
The p120 RasGAP protein negatively regulates Ras via its GAP domain. RasGAP carries several other 
domains that modulate various signaling molecules such as Rho. RasGAP is also a caspase-3 substrate. One 
of the caspase-3-generated RasGAP fragments, corresponding to amino acids 158-455 and called fragment 
N2, was previously reported to specifically sensitize cancer cells to death induced by various anticancer 
agents. Here we show that fragment N2 inhibits migration in vitro and that it impairs metastatic progression 
of breast cancer to the lung. Hence, stress-activated caspase-3 might contribute to the suppression of 
metastasis through the generation of fragment N2. These results indicate that the activity borne by fragment 
N2 has a potential therapeutic relevance to counteract the metastatic process. 
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INTRODUCTION 
Metastasis is responsible for most cancer-related deaths1 but preventing or inhibiting metastasis 
formation remains a challenge. Understanding the molecular mechanisms involved in the metastatic 
cascade is therefore crucial to develop therapeutical anti-metastatic drugs. Metastatic progression is a 
complex multistep process that includes the escape of cancer cells from the primary tumor, the 
intravasation into the lymphatic or hematogenous systems, the extravasation into the parenchyma of new 
distant sites and the colonization of these sites.2 These steps are associated with increased motility, 
invasiveness, cell-cell binding modulation, and decreased adhesion of cells to their substratum.2 Targeting 
specifically the molecular pathways that affect cell adhesion and migration represents prime anti-cancer 
strategies. 
Among the most commonly deregulated signaling proteins in cancer are the Ras protein.3 These 
are activated by guanine nucleotide exchange factors (GEFs) and negatively modulated by GTPase-
activating proteins (GAPs).4 There are ten different GAPs that regulate Ras5 including DAB2IP and Rasal2 
that have recently been found to be dual tumor and metastasis suppressors.6,7 Whether other RasGAPs act 
as metastasis suppressors remains unknown. 
p120 RasGAP (from now on referred to as RasGAP) is more than a mere negative modulator of 
the Ras pathway via its GAP domain.8 Indeed its N-terminal moiety contains multiple domains, including 
SH2 and SH3 domains, that positively modulate kinases such as Cdk1.9 The N-terminal region of RasGAP, 
in contrast to its C-terminal end, can lead to Ras activation.10 This can explain for example why there is a 
weaker basal Ras activity in cells lacking RasGAP compared to wild-type cells.11 RasGAP can therefore 
negatively or positively control Ras activation in a manner that is probably cell- and stimulus-dependent. 
RasGAP is also a caspase-3 substrate. The RasGAP/caspase-3 pair forms a stress-sensing module that 
induces survival signals in homeostasis perturbing conditions and apoptosis in the presence of excessive 
stress.12 Stress sensing by this module relies on differential cleavage of RasGAP at low and high caspase-3 
activity. In the presence of a low stress, caspase-3 cleaves RasGAP once, generating an amino-terminal 
fragment, called fragment N, that efficiently promotes cell survival in Ras/PI3K/Akt-dependent 
manner.10,13,14 When the stress reaches unsustainable levels, caspase-3 further cleaves fragment N into two 
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smaller fragments, called N1 and N2, that no longer have the ability of stimulating Akt.15 This terminates 
the Akt-dependent protecting signals, thereby favoring cell death. 
Fragment N2 favors pro-apoptotic signaling, in cancer cells but not in non-malignant cells, in 
response to various anti-cancer agents.16 Recently, fragment N2 was found to increase the adhesive 
capacity of cells.17 This activity is carried by a ten amino acid sequence within fragment N2 that correspond 
to amino acid 317-326 of RasGAP.17 These findings prompted us to test the ability of fragment N2 to 
inhibit metastatic progression in vivo. Here we show that fragment N2 hampers malignant cells to escape 
the primary tumor site. This indicates that an internal portion of RasGAP, which can be released by 
caspase-3 cleavage, can act as a metastasis suppressor. 
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MATERIAL AND METHODS 
 
Cell lines, cell culture, lentiviral infection, Western blotting and wound-healing assay 
All cell lines were maintained in Dulbecco’s Modified Eagle Medium as previously described.17 
Recombinant lentivirus production,18 Western blotting and wound healing assays were performed as 
previously reported.17  
 
Generation of stable 4T1 clones 
4T1 cells were transfected with the pEGFP-C1 and pTK-Hyg  (3:1 ratio) or with GFP-HA-hRasGAP[158-
455] and pTK-Hyg (3:1 ratio) using the calcium phosphate method as previously reported.17 The cells were 
selected using hygromycin B (selection: 200 µg/ml; maintenance: 100 µg/ml) until appearance of colonies. 
GFP-positive colonies were picked, and screened by microscopy and immunoblotting. Plasmids used in this 
study are described in the supplementary methods. 
 
Antibody description 
The antibodies used in this study were obtained from the following sources: anti-GFP (JL-8) (Clontech; ref: 
632381; 1:2500), anti-RasGAP (Enzo life sciences; ref: ALX-210-860-R100; 1:250), anti-β-actin 
(Chemicon International Inc; ref: MAB1501; 1:5000) and anti-HA (Covence; ref: MMS-101r; 1:1000). The 
secondary antibodies were IRDye800-conjugated anti-mouse IgG (Rockland; ref: 610-132-121; 1:5000; 
milk) and AlexaFluor680-conjugated anti-rabbit IgG (Molecular Probes; ref: A21109; 1:5000; milk). 
 
4T1 orthotopic model 
We carried out orthotopic implantations as previously described19 and under authorization license (Swiss 
Animal Protection Ordinance; permit number: 2379). Briefly, Balb/c female mice (Charles River) with 
100’000 murine mammary cancer 4T1-derived stable clones in 20 % Matrigel (BD Biosciences; ref: 
354248; diluted in PBS). The mice were sacrificed after 29 days and analyzed for the presence of lung 
metastases. The analyses involving TAT-RasGAP317-326 injection are described in the supplementary 
methods. 
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Primary tumor and metastasis measurement  
Tumor volumes were quantified as described earlier.20 For metastasis analyses, five equidistant sections per 
lung were performed and stained with hematoxylin/eosin (H/E). The number of metastatic foci was 
reported as the mean of the five slides per organ and normalized to the maximal effect per experiment. The 
metastatic index was calculated by dividing the normalized number of metastatic foci by the corresponding 
mouse tumor weight (normalized to the maximal effect per experiment).  
 
Experimental metastasis assay 
Experimental metastasis assays were performed as previously reported.21 Experimental details appear in the 
supplementary methods. Briefly, nude NMRI mice were injected with fragment N2 stably expressing 
MDA-MB-231-Luc (that stably express firefly luciferase) cells and sacrificed after 46 days. 
Bioluminescence of the lungs was assessed as described in the supplementary methods.  
 
Statistical analysis 
The statistical tests were achieved using the R software (version 2.11.0). The tumor growth and migration 
assays were analyzed by repeated measurement ANOVAs. Every metastasis and tumor size analyses were 
analyzed by non-parametric Mann-Whitney U tests. The Bonferroni correction was applied when more 
than one comparison was performed. Asterisks denote statistical differences (*: p-value < 0.05; **: p-value 
< 0.01 after Bonferonni corrections). Box plot description appears in the supplementary methods. Except 
when displayed as box plots, the results were expressed as mean +/- 95% confidence intervals.  
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RESULTS 
To evaluate the role of fragment N2 during metastatic progression, we used the well-established 
4T1 murine breast cancer model.22 4T1 cells, when implanted orthotopically in the mammary fat pad of 
syngeneic Balb/c mice, efficiently metastasize to the lungs.22 We therefore generated several 4T1 clones 
expressing fragment N2 fused to a green fluorescent protein (GFP) or GFP alone as controls. Most of these 
clones express elevated levels of GFP and GFP-fragment N2 (from now referred to as GFP-N2) as revealed 
by immunoblotting (Figure 1A) and fluorescence microscopy (Figure 1B). All clones expressing fragment 
N2 displayed impaired motile capacity (Figure 1C). Of note, even the GFP-N2 #6 and #8 clones in which 
GFP-fragment N2 is degraded exhibited reduced migration. 
Since fragment N2 efficiently inhibits migration, we evaluated its in vivo capacity to prevent 
metastasis formation to the lungs. We selected two GFP (#3 and #5) and two GFP-N2 (#9 and #10) clones 
to minimize the risk of generating clone-specific effects. When implanted in the mammary gland, all clones 
produced similarly sized primary tumors (Figure 2A) and of comparable weight after 29 days (Figure 2B). 
This indicates that fragment N2 does not affect tumor take and tumor growth. In contrast, the number of 
lung metastasis was significantly lower in mice bearing primary tumors that express fragment N2 (Figure 
2C). Consistently, the metastatic index (number of metastasis corrected for the primary tumor weight) of 
the N2-expressing clones was significantly lower than the metastatic index of GFP-expressing clones 
(Figure 2D). These data indicate that expression of fragment N2 impairs metastatic progression. 
Noteworthily, fragment N2 did not affect the epithelial-to-mesenchymal transition (EMT), a process 
implicated in metastatic dissemination23 because the levels of E-cadherin or vimentin, two hallmark 
molecules modulated during EMT, remained unchanged in 4T1 clones overexpressing fragment N2 (data 
not shown). 
To determine the stability of fragment N2 expression in the 4T1 clones in vivo, we injected five 
mice with 4T1 GFP-N2 #10, sacrificed them at different time points and analyzed the expression of GFP-
N2. This experiment revealed that expression of GFP-N2 was partially lost 16 days after tumor 
implantation and completely abrogated 22 days after implantation (Figure 2E). In contrast, the GFP-N2 
#10 clone cultured in vitro did not lose fragment N2 expression during this time frame (Figure 2E). Loss of 
fragment N2 expression from tumors growing in mice may be an indication that this fragment exerts some 
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tumor suppressive effects. One could therefore conceive that if fragment N2 expression was not 
progressively disappearing during the in vivo metastasis development experiment, the 4T1 clones initially 
expressing fragment N2 would have produced much fewer metastases than those actually observed. 
Cell migration is considered to contribute to metastasis at two discrete steps in the metastatic 
cascade: at an early metastatic stage when cells escape from the primary tumor and again at a later stage 
when cells extravasate and invade the parenchyma of the newly colonized site. The 4T1 in vivo model does 
not allow differentiating whether fragment N2 inhibits escape from the primary tumor, colonization of the 
secondary site or both. To assess whether fragment N2 inhibits the capacity of circulating tumor cells to 
invade tissues, the breast cancer MDA-MB-231 cell line expressing the luciferase gene and freshly infected 
with lentiviruses expressing or not fragment N2 were injected in the bloodstream of nude mice. Their 
capacity to colonize lungs was then evaluated by measuring the luciferase activity in these organs 46 days 
after the injection. Figure 2F shows that fragment N2 did not alter the capacity of MDA-MB-231 cells to 
invade the lungs. There was no or minimal loss of fragment N2 in the fragment N2-infected cells during the 
time-course of this experiment (blot of Figure 2F). Altogether, these experiments indicate that fragment 
N2 inhibits metastatic progression by preventing cancer cells from escaping the primary site but not by 
inhibiting colonization of distal sites. 
As fragment N2 inhibits migration, a logical follow up was to assess whether the cell-permeable 
TAT-RasGAP317-326 peptide was also able to inhibit metastasis formation. TAT-RasGAP317-326, when 
injected intraperitoneally, was shown to accumulate in subcutaneously established HCT116 tumors and to 
improve the effects of chemotherapy on preventing the growth of these tumors.20 Unfortunately, HCT116 
tumors do not metastasize to other organs and hence could not be employed here to investigate the anti-
metastatic potential of TAT-RasGAP317-326. We therefore used the 4T1 model instead. However, this model 
is not ideal in the present setting because 125I-labelled TAT-RasGAP317-326 injected intraperitoneally failed 
to accumulate in primary 4T1 tumors (supplementary Figure 1A). Our conclusion that the peptide did not 
accumulate in the tumor derives from the fact that the radioactive values in the tumor were even lower than 
the residual signal found in the blood (supplementary Figure 1A). In contrast, it accumulated in the liver 
as shown previously (supplementary Figure 1A).20 Moreover, it is impossible to test if the weakly 
delivered TAT-RasGAP317-326 dose has sufficient functional effects as 4T1 cells are not sensitive to 
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genotoxins and could therefore not be tested for sensitization to apoptosis. We nevertheless, tested whether 
the RasGAP peptide could affect the ability of 4T1 cells to metastasize. Starting at the time of 4T1 tumors 
cells in the fat pad, mice were injected three times a week with 1.6 mg/kg TAT-RasGAP317-326. The 
primary tumor size and weight were not affected by the peptide treatment (supplementary Figure 1B-C). 
Twenty-five days after tumor injection, the mice were sacrificed and the lungs were analyzed for the 
presence of metastases. TAT-RasGAP317-326-treated mice did not display fewer metastatic foci 
(supplementary Figure 1D). As the peptide does not apparently accumulate in 4T1 tumors, the negative 
nature of these experiments do not allow us to conclude whether TAT-RasGAP317-326 inhibits or not 
metastasis formation. 
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DISCUSSION 
Cancer therapy still suffers from a lack of metastasis-specific drugs. Only a few of them are used 
in the clinics to treat specific cancers while the majority remains in early clinical trials.24 Here, we provide 
the proof of concept that the fragment N2 of RasGAP acts as a metastasis suppressor. Hence, compounds 
bearing fragment N2 anti-metastatic activity may have the potential for the development of 
pharmacological compounds with anti-metastatic activities. We have derived a cell-permeable protease-
resistant 10 amino acid peptide corresponding to a short region of fragment N2. This compound, called 
TAT-RasGAP317-326, efficiently sensitizes cancer cells to various anti-tumor treatments, both in vitro and in 
vivo.16,20 It also increases cell adherence, blocks cell migration and prevents invasion.17 This TAT-
RasGAP317-326 peptide has therefore the potential to inhibit metastasis development in vivo. Unfortunately, 
the experiment we have performed here did not allow us to determine whether TAT-RasGAP317-326 acts as 
a metastasis blocker because this compound failed to accumulate in breast-implanted 4T1 tumors. Thus, 
testing this hypothesis needs to await the development of compounds able to accumulate at sufficient levels 
in primary tumors and/or target organs.  The prototypical issues associated with peptide therapeutics are the 
clearance by the liver, the weak selectivity of delivery and the peptide short half-lives. In the case of TAT-
RasGAP317-326 this last concern has been circumscribed by using D-amino acids for its synthesis but there is 
still room for improvement concerning the first two issues.25,26 The development of small molecules 
mimicking the activity of TAT-RasGAP317-326 is a suited alternative. We recently found that deleted in liver 
cancer-1 (DLC1), a RhoGAP and metastasis suppressor, was required by TAT-RasGAP317-326 to prevent 
migration.17 Work based on the interaction between fragment N2 and DLC1 could potentially lead to the 
development of a small molecule with TAT-RasGAP317-326-like activities. 
Fragment N2 can be produced endogenously in response to stress,12 although probably not to the 
levels obtained in the clones used in the present study. One could anticipate that the endogenous fragment 
N2 plays some physiological roles, potentially in the context of malignant transformation. In cancer 
development, pre-malignant cells experience oncogenic stress that induces caspase activation leading to 
apoptosis in many but not all cells.27 There are indeed cases, such as in breast cancer, where caspase-3 
activity is higher in malignant tissues than in corresponding normal ones.28 Because of caspase activation, 
the surviving cells may produce fragment N2 that has then the potential to exert two tumor suppressor 
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functions. First, fragment N2 can render cancer cells more sensitive to stress-induced death and therefore 
contribute to their elimination if the first wave of caspase activation failed to do so. Second, fragment N2 
can prevent dissemination of surviving cancer cell hence blocking metastasis formation. 
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FIGURE LEGENDS 
Figure 1. Stable expression of fragment N2 inhibits cell migration.  
A. Stable 4T1 clones were screened for expression of GFP and GFP-N2 by immunoblotting against GFP 
and RasGAP. 
B. Representative images of GFP-positive 4T1 stable clones. The nucleus of untransfected 4T1 cells is also 
shown by Hoechst-33342 staining. Scale bar: 50 µm.  
C. Stable 4T1 clones were subjected to wound-healing scratch assays. The left panel displays the 
progression of wound width over time for every clones (n=1 experiment). The right panel displays the 
percentage of wound closure for the clones that were selected for further experiments (n=4 experiments). 
Asterisks denote significant differences between the indicated groups after repeated measurement ANOVA.   
 
Figure 2. Fragment N2 inhibits metastatic progression. 
A-E. Balb/c mice were injected with four stable 4T1 clones expressing GFP (#3 and #5) or GFP-N2 (#9 
and #10). The experiments were performed three times independently using 4-6 mice per condition in each 
experiment. The data were pooled per condition. The figure displays the tumor growth (A), the tumor 
weight after sacrifice (B), the normalized number of metastatic foci per lung (C), and the metastatic index 
(D). Of note, when pooling GFP clones together and GFP-N2 clones together, the GFP-N2 group exhibits a 
highly significant metastatic index decrease over the GFP group (p=0.00012).  
E. 4T1-GFP-N2 #10 cells were implanted orthotopically (in vivo) or maintained in culture (in vitro). 
Immunoblotting against RasGAP was performed for the indicated time. ). The ~40 kDa fragment detected 
at 11 days in vitro, and apparently in the in vivo condition as well, corresponds to the similarly sized 
fragment observed in the GFP-N2 #6 and #8 clones (see Figure 1A, upper blot). Based on the size of this 
fragment and the fact that it is recognized by the anti-RasGAP antibody, it can be assumed that it contains 
the entirety of fragment N2. 
F. An experimental metastasis assay was done by injecting MDA-MB-231-Luc cells infected with 
fragment N2 (or its empty vector). The bioluminescence and the number of lung-invading cells are reported 
in the graph. Seven to eight mice were analyzed per condition. Immunoblotting against the HA tag and β-
actin is displayed on the left for cells that were maintained in culture during the time-frame of the assay.  
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In panels B, C, D, and F, the results are shown as boxplots on the left while raw data points are displayed 
on the right. 
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SUPPLEMENTARY MATERIAL AND METHODS 
 
Plasmid description 
The extension .dn3 indicates that the backbone plasmids are pcDNA3 (#1) from Invitrogen. The pEGFP-
C1 (#6) plasmid encodes the green fluorescent protein and is from Clontech (ref: 6084-1). The pTK-Hyg 
(#317) plasmid encodes for a protein that confers resistance to the hygromycin B (Roche; ref: 12653400) 
and is from Clontech (ref: 6153-1). HA-hRasGAP[158-455].dn3 (#145) previously called HA-N2.dn3 (1), 
encodes the HA-tagged form of fragment N2. GFP-HA-hRasGAP[158-455] (#213), previously named 
GFP-HA-N2 (2) encodes an HA-tagged version of fragment N2 fused with a GFP-protein at the N-
terminal. The HA-hRasGAP[158-455].lti (#769) used for lentiviral infection was described earlier (3). 
 
Experimental metastasis assay 
Experimental metastasis assays were performed as previously reported (4). Nude mice were used (Janvier; 
ref: Rj:NMRI-Foxn1nu/Foxn1nu) and MDA-MB-231 firefly-luciferase expressing cell were injected. Peptide 
regimen was similar than with 4T1 model except that it last for 30 days. Alternatively, MDA-MB-231 were 
infected by lentiviruses encoding the RasGAP Fragment N2 (or its empty vector), then were injected in the 
tail vein and sacrificed after 46 days. Lungs were taken out. The blood that was remaining in the lungs was 
washed by PBS perfusion into the right cardiac ventricle. The left lobes were weighed, lyzed and 20 µg of 
lung lysate were analyzed for luciferase activity using the GloMax luminometer and according to the 
manufacturer’s instructions (Promega; ref: E6521). The results were reported in relative light units (R.L.U.) 
and in number of cells as known number of cells were quantified in vitro for their bioluminescence. 
 
TAT-RasGAP317-326 synthesis 
The TAT-RasGAP317-326 peptide (GRKKRRQRRRGGWMWVTNLRTD) was described and synthesized 
as previously reported (5;6).  
 
 2 
Radioiodination of the TAT-Y-RasGAP317-326 peptide 
Ten MBq Na[I125]-Iodide (Perkin Elmer) were added to 4.8 µl of 1 mM TAT-Y-RasGAP317-326 
(GRKKRRQRRRGYGWMWVTNLRTD) in a glass vial coated with 100 µg iodogen (Iodination reagent; 
Pierce; ref: 28600). The vial was placed on ice for 20 minutes. The mixture was diluted up to 1 ml with 
gelatin eluting buffer (0.25 % gelatin in PBS (w/v)) and then loaded on a PD Minitrap G-10 column (GE 
Healthcare; ref: 28-9180-10). The radiolabeled peptide was then eluted in 0.5 ml gelatin elution buffer. 
 
TAT-RasGAP317-326 biodistribution 
Five Balb/c mice were injected with one hundred thousand 4T1 cells in the mammary fat pads. Fourteen 
days after cancer cell injection, the mice were injected with 1.6 mg/kg TAT-RasGAP317-326 peptide 
(containing 5 % (v/v) of I125-radiolabeled peptide). Six hours after, the mice were sacrificed and the 4T1 
tumor and organ radioactivity were recorded in counts per minute (cpm). Since the radioactivity of the 
whole mouse was recorded, the percentage of the injected dose per organ could be calculated. 
 
4T1 orthotopic model with TAT-RasGAP317-326 
We carried out orthotopic implantations as described in the material and methods. Mice treated with the 
RasGAP peptide were injected intraperitoneally with 1.6 mg/kg TAT-RasGAP317-326 (or its vehicle: PBS) 
three times a week (every monday, wednesday and friday) and sacrificed after 25 days.  
 
Boxplot description 
Boxplots were performed as follows: the line in a box indicates the median; the box contains 50% of values 
(i.e. 25% of those above and 25% of those below the median); whisker's length corresponds to 1.5 time of 
the box's length (if shorter, the length of the whisker reaches the lowest or the highest value of the data set). 
Empty circles represent outlier values (i.e. outside the range covered by the box and the whiskers). 
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Supplementary Figure 1. Effect of TAT-RasGAP317-326 on 4T1 metastasis formation.
(A) The biodelivery of 1.6 mg/kg I125-labelled TAT-RasGAP317-326 in Balb/c bearing pre-established 4T1 tumors was 
reported in percentage of the injected dose (n = 5 mice).
(B-D) Balb/c mice were injected with 4T1 cells and then treated three times a week with 1.6 mg/kg TAT-RasGAP317-
326 for 25 days. The figure displays the tumor growth (B), the tumor weight after sacrifice (C) and the number of 
metastatic foci per lung (D). Ten mice per condition were analyzed. The results are shown as boxplots on the left 
while raw data points are displayed on the right.
